Use of a recombinant Burkholderia intracellular motility a protein for immunodiagnosis of glanders

Subodh Kumar, Praveen Malik, Shailendra Kumar Verma, Vijai Pal, Vandana Gautam, Chiranjay Mukhopadhyay, Ganga Prasad Rai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Glanders, caused by the Gram-negative, nonmotile bacterium Burkholderia mallei, is a contagious and highly fatal disease of equines. During the last decade, the number of glanders outbreaks has increased steadily. The disease also has high zoonotic significance and B. mallei is listed biological warfare agent. The complement fixation test (CFT) is a routinely used and internationally recognized test to screen equine sera for the glanders. However, discrepant results have been observed using the CFT. The low sensitivity and specificity of the CFT and enzyme-linked immunosorbent assay (ELISA) have been linked to the use of crude test antigens. We expressed a novel recombinant Burkholderia intracellular motility A (rBimA) protein in Escherichia coli for the diagnosis of equine glanders. Purified rBimA was used in an indirect ELISA format. All of the 21 true-positive serum samples used in the study tested positive, whereas only 17 of the 1,524 potentially negative sera tested positive by indirect ELISA, thus exhibiting 100% sensitivity and 98.88% specificity. Also, rBimA protein did not react with melioidosis patient and normal healthy human serum samples, showing its high specificity. The developed assay can be used as a simple and rapid tool for diagnosis of glanders in equine serum samples. An Indian patent (1328/DEL/2010) has been filed for the reagent.

Original languageEnglish
Pages (from-to)1456-1461
Number of pages6
JournalClinical and Vaccine Immunology
Volume18
Issue number9
DOIs
Publication statusPublished - 01-09-2011

Fingerprint

Glanders
Molecular Motor Proteins
Burkholderia
Immunologic Tests
Immunosorbents
Assays
Complement Fixation Tests
Burkholderia mallei
Horses
Serum
Enzyme-Linked Immunosorbent Assay
Proteins
Enzymes
Biological Warfare Agents
Melioidosis
Sensitivity and Specificity
Escherichia coli
Zoonoses
Bacteria
Gram-Negative Bacteria

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Kumar, Subodh ; Malik, Praveen ; Verma, Shailendra Kumar ; Pal, Vijai ; Gautam, Vandana ; Mukhopadhyay, Chiranjay ; Rai, Ganga Prasad. / Use of a recombinant Burkholderia intracellular motility a protein for immunodiagnosis of glanders. In: Clinical and Vaccine Immunology. 2011 ; Vol. 18, No. 9. pp. 1456-1461.
@article{3462fab024f44a7d885f96b1a11f7bcd,
title = "Use of a recombinant Burkholderia intracellular motility a protein for immunodiagnosis of glanders",
abstract = "Glanders, caused by the Gram-negative, nonmotile bacterium Burkholderia mallei, is a contagious and highly fatal disease of equines. During the last decade, the number of glanders outbreaks has increased steadily. The disease also has high zoonotic significance and B. mallei is listed biological warfare agent. The complement fixation test (CFT) is a routinely used and internationally recognized test to screen equine sera for the glanders. However, discrepant results have been observed using the CFT. The low sensitivity and specificity of the CFT and enzyme-linked immunosorbent assay (ELISA) have been linked to the use of crude test antigens. We expressed a novel recombinant Burkholderia intracellular motility A (rBimA) protein in Escherichia coli for the diagnosis of equine glanders. Purified rBimA was used in an indirect ELISA format. All of the 21 true-positive serum samples used in the study tested positive, whereas only 17 of the 1,524 potentially negative sera tested positive by indirect ELISA, thus exhibiting 100{\%} sensitivity and 98.88{\%} specificity. Also, rBimA protein did not react with melioidosis patient and normal healthy human serum samples, showing its high specificity. The developed assay can be used as a simple and rapid tool for diagnosis of glanders in equine serum samples. An Indian patent (1328/DEL/2010) has been filed for the reagent.",
author = "Subodh Kumar and Praveen Malik and Verma, {Shailendra Kumar} and Vijai Pal and Vandana Gautam and Chiranjay Mukhopadhyay and Rai, {Ganga Prasad}",
year = "2011",
month = "9",
day = "1",
doi = "10.1128/CVI.05185-11",
language = "English",
volume = "18",
pages = "1456--1461",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "9",

}

Use of a recombinant Burkholderia intracellular motility a protein for immunodiagnosis of glanders. / Kumar, Subodh; Malik, Praveen; Verma, Shailendra Kumar; Pal, Vijai; Gautam, Vandana; Mukhopadhyay, Chiranjay; Rai, Ganga Prasad.

In: Clinical and Vaccine Immunology, Vol. 18, No. 9, 01.09.2011, p. 1456-1461.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of a recombinant Burkholderia intracellular motility a protein for immunodiagnosis of glanders

AU - Kumar, Subodh

AU - Malik, Praveen

AU - Verma, Shailendra Kumar

AU - Pal, Vijai

AU - Gautam, Vandana

AU - Mukhopadhyay, Chiranjay

AU - Rai, Ganga Prasad

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Glanders, caused by the Gram-negative, nonmotile bacterium Burkholderia mallei, is a contagious and highly fatal disease of equines. During the last decade, the number of glanders outbreaks has increased steadily. The disease also has high zoonotic significance and B. mallei is listed biological warfare agent. The complement fixation test (CFT) is a routinely used and internationally recognized test to screen equine sera for the glanders. However, discrepant results have been observed using the CFT. The low sensitivity and specificity of the CFT and enzyme-linked immunosorbent assay (ELISA) have been linked to the use of crude test antigens. We expressed a novel recombinant Burkholderia intracellular motility A (rBimA) protein in Escherichia coli for the diagnosis of equine glanders. Purified rBimA was used in an indirect ELISA format. All of the 21 true-positive serum samples used in the study tested positive, whereas only 17 of the 1,524 potentially negative sera tested positive by indirect ELISA, thus exhibiting 100% sensitivity and 98.88% specificity. Also, rBimA protein did not react with melioidosis patient and normal healthy human serum samples, showing its high specificity. The developed assay can be used as a simple and rapid tool for diagnosis of glanders in equine serum samples. An Indian patent (1328/DEL/2010) has been filed for the reagent.

AB - Glanders, caused by the Gram-negative, nonmotile bacterium Burkholderia mallei, is a contagious and highly fatal disease of equines. During the last decade, the number of glanders outbreaks has increased steadily. The disease also has high zoonotic significance and B. mallei is listed biological warfare agent. The complement fixation test (CFT) is a routinely used and internationally recognized test to screen equine sera for the glanders. However, discrepant results have been observed using the CFT. The low sensitivity and specificity of the CFT and enzyme-linked immunosorbent assay (ELISA) have been linked to the use of crude test antigens. We expressed a novel recombinant Burkholderia intracellular motility A (rBimA) protein in Escherichia coli for the diagnosis of equine glanders. Purified rBimA was used in an indirect ELISA format. All of the 21 true-positive serum samples used in the study tested positive, whereas only 17 of the 1,524 potentially negative sera tested positive by indirect ELISA, thus exhibiting 100% sensitivity and 98.88% specificity. Also, rBimA protein did not react with melioidosis patient and normal healthy human serum samples, showing its high specificity. The developed assay can be used as a simple and rapid tool for diagnosis of glanders in equine serum samples. An Indian patent (1328/DEL/2010) has been filed for the reagent.

UR - http://www.scopus.com/inward/record.url?scp=80052433275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052433275&partnerID=8YFLogxK

U2 - 10.1128/CVI.05185-11

DO - 10.1128/CVI.05185-11

M3 - Article

VL - 18

SP - 1456

EP - 1461

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 9

ER -